Cellectar Biosciences (CLRB) vs Cerenome (CNSY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cellectar Biosciences (CLRB) has outperformed Cerenome (CNSY) over the past year, losing 69.6% versus a loss of 89.3%. Over five years, CLRB leads with a -99.5% price change compared with -99.7% for CNSY. Cerenome is the larger company by market cap ($14.6 million vs $13.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | CNSY |
|---|---|---|
| Share price | $1.45 | $1.93 |
| Market cap | $13.71M | $14.65M |
| 1-day change | +3.57% | +7.82% |
| YTD return | -50.85% | -84.86% |
| 1-year return | -69.60% | -89.28% |
| 5-year return | -99.47% | -99.71% |
| EPS (TTM) | $-3.46 | $-3.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $19.00 |
| 52-week low | $1.34 | $1.49 |
| Distance from 52-week high | -71.40% | -89.84% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +693.10% | +1337.82% |
| Average volume | 64.22K | 122.41K |
| Shares outstanding | 9.45M | 7.59M |
| Employees | 11 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLRB has outperformed CNSY by 19.7 percentage points over the past year.
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
CLRB vs CNSY FAQ
Which is bigger, Cellectar Biosciences or Cerenome?
Cerenome (CNSY) is larger, with a market capitalization of $14.65M compared with $13.71M for Cellectar Biosciences (CLRB).
Which stock has performed better over the past year, CLRB or CNSY?
CLRB returned -69.60% over the past 12 months, compared with -89.28% for CNSY (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Cerenome in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Cellectar Biosciences and Medical/Dental Instruments for Cerenome.